Mai Capital Management Neurocrine Biosciences Inc Transaction History
Mai Capital Management
- $13 Billion
- Q1 2025
A detailed history of Mai Capital Management transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Mai Capital Management holds 163 shares of NBIX stock, worth $19,589. This represents 0.0% of its overall portfolio holdings.
Number of Shares
163
Previous 280
41.79%
Holding current value
$19,589
Previous $38,000
52.63%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding NBIX
# of Institutions
650Shares Held
97.2MCall Options Held
749KPut Options Held
553K-
Black Rock Inc. New York, NY14.2MShares$1.71 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.94MShares$1.19 Billion0.02% of portfolio
-
Dodge & Cox San Francisco, CA5.53MShares$665 Million0.37% of portfolio
-
State Street Corp Boston, MA4.86MShares$584 Million0.02% of portfolio
-
Jpmorgan Chase & CO New York, NY2.67MShares$321 Million0.02% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $11.5B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...